GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk Safety and reactogenicity data are consistent ...

That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial. The trial initially enrolled about ...

(Reuters) – U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and pregnant women. It leads to symptoms ranging from mild colds to severe ...

Additional data from the phase 3 trial showed the vaccine came with a 94.1% effectiveness in preventing severe RSV when people got it during the first season and 64.2% a year later, the company ...

Across the entire time period, one dose of Arexvy was 63% effective against RSV broadly, and 67% effective against severe disease, GSK said. However, the shot’s efficacy waned, falling to an estimated ...

LONDON (Reuters) – Pfizer on Monday won a bid in a London court to invalidate two of GSK’s patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a ...

LONDON (Reuters) – Pfizer on Monday won a bid in a London court to invalidate two of GSK’s patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are ...

It had a weaker-than-hoped launch of its respiratory syncytial virus (RSV) vaccine and clinical data from an obesity pill it was developing has been disappointing. CEO Bourla has also spent some $ ...

NBC’s medical contributors Dr. Natalie Azar and Dr. John Torres discuss the rising risks of RSV and whooping cough this year, how to differentiate allergies from a more serious virus ...

Investing.com -- One of the biggest contract drug manufacturing plants in the US owned by Thermo Fisher Scientific (NYSE:TMO) has repeatedly broken rules designed to ensure that medications are ...

to prevent infections with respiratory syncytial virus (RSV). While Sanofi (SNY) and the FDA said issues were resolved since then in compliance with regulatory standards, over the past ten years ...